[{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Heparin Blausiegel","moa":"Antithrombin III","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VX-147","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Limoges","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"University Hospital, Limoges","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Limoges \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital, Limoges \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","highestDevelopmentStatusID":"9","companyTruncated":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University "},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"China Agricultural University","sponsor":"Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"China Agricultural University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Agricultural University \/ Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"China Agricultural University \/ Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd."},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Calcium Acetate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TRK-100STP","moa":"Prostacyclin receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Astellas Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Toray Industries \/ Astellas Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare"},{"orgOrder":0,"company":"VieCuri Medical Centre","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Troponin, cardiac muscle | Phosphodiesterase 3","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"VieCuri Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VieCuri Medical Centre \/ Orion Corporation","highestDevelopmentStatusID":"9","companyTruncated":"VieCuri Medical Centre \/ Orion Corporation"},{"orgOrder":0,"company":"Weill Cornell Medical College in Qatar","sponsor":"Hamad Medical Corporation | Weill Medical College of Cornell University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"QATAR","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Weill Cornell Medical College in Qatar","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medical College in Qatar \/ Hamad Medical Corporation | Weill Medical College of Cornell University","highestDevelopmentStatusID":"9","companyTruncated":"Weill Cornell Medical College in Qatar \/ Hamad Medical Corporation | Weill Medical College of Cornell University"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Serodus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SER150","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Serodus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Serodus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Serodus \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Japan Blood Products Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GB-0998","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Japan Blood Products Organization","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Blood Products Organization \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Japan Blood Products Organization \/ Undisclosed"},{"orgOrder":0,"company":"Kibow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KT-301","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Kibow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kibow Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kibow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ebima Clifford Okundaye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QRX-3","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Ebima Clifford Okundaye","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ebima Clifford Okundaye \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ebima Clifford Okundaye \/ Undisclosed"},{"orgOrder":0,"company":"Ebima Clifford Okundaye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QRX-3","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Ebima Clifford Okundaye","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ebima Clifford Okundaye \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ebima Clifford Okundaye \/ Undisclosed"},{"orgOrder":0,"company":"Advicenne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADV7103","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advicenne \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Advicenne \/ Undisclosed"},{"orgOrder":0,"company":"Advicenne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADV7103","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advicenne \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Advicenne \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital"},{"orgOrder":0,"company":"Danderyd Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Danderyd Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danderyd Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"9","companyTruncated":"Danderyd Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Neukidney Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eseronate","moa":"NADPH oxidase","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Neukidney Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neukidney Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neukidney Inc \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radboud University Medical Center \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Radboud University Medical Center \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apellis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Apellis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Roberto Gedaly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Roberto Gedaly","highestDevelopmentStatusID":"9","companyTruncated":"Veloxis Pharmaceuticals \/ Roberto Gedaly"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Pegcetacoplan is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulosclerosis, Focal Segmental.
Details :
Povetacicept is a Protein drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulonephritis, Membranous.
Details :
Eseronate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Acute Kidney Injury.
Details :
Obinutuzumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulonephritis, Membranous.
Details :
Encaleret is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Hypocalcemia.
Details :
QRX-3 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Details :
B007 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Primary Membranous Nephropathy.
Details :
Dapagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Details :
Zanubrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Primary Membranous Nephropathy.
Reset All
